Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gibb

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
BJU International|October 7, 2023
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancerAndrea Necchi, Giuseppe Basile, Ewan A Gibb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
European Urology Oncology|May 18, 2020
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 StudyAndrea Necchi, Daniele Raggi, Patrizia Giannatempo, et al.
Urologic Oncology|May 31, 2022
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Nature Communications|January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancerGillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Molecular Cancer Therapeutics|September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder CancerTilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
British Journal of Haematology|April 21, 2023
CAR T in patients with large B-cell lymphoma not fit for autologous transplantA Kuhnl, A A Kirkwood, C Roddie, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
BJU International|October 7, 2023
Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancerAndrea Necchi, Giuseppe Basile, Ewan A Gibb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab VedotinCarissa E Chu, Martin Sjöström, Emily A Egusa, et al.
Urologic Oncology|December 9, 2019
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapyPetros Grivas, Tarek A Bismar, Aijai S Alva, et al.
European Urology Oncology|May 18, 2020
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 StudyAndrea Necchi, Daniele Raggi, Patrizia Giannatempo, et al.
Urologic Oncology|May 31, 2022
Corrigendum to: Mechanistic target of rapamycin (mTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Urologic Oncology|April 17, 2018
Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomyBrian R Winters, Funda Vakar-Lopez, Lisha Brown, et al.
Nature Communications|January 9, 2021
Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancerGillian Vandekerkhove, Jean-Michel Lavoie, Matti Annala, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Molecular Cancer Therapeutics|September 29, 2018
Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder CancerTilman Todenhöfer, Roland Seiler, Craig Stewart, et al.
British Journal of Haematology|April 21, 2023
CAR T in patients with large B-cell lymphoma not fit for autologous transplantA Kuhnl, A A Kirkwood, C Roddie, et al.
Pageof 21